論文
2026年
Nakashima I, Ohashi T, Yokoyama K, Kaida K, Nakahara J, Kondo T, Yoshikura N, Shimizu Y, Nohara C, Sakurai K, Yokote H, Niino M, Yamamura T,
Fujihara K, Isobe N, Ochi H, Mori M, Kawachi I, Shimizu F, Kanda M, Tani Y, Fukazawa T.
A multicenter, retrospective study in patients with multiple sclerosis treated with natalizumab in a real-world setting in Japan: the REFIND study.
Mult Scler Relat Disord, 2026 NEW Jan, in press
Fujihara K, Isobe N, Miyamoto K, Niino M, Nakahara J, Hattori S, Tanaka M, Tahara M, Suzumura A, Sakurai K, Yoshikura N, Shiomi K, Ochi H, Nagata E, Deguchi K, Tomizawa Y, Yamashita K, Nagatsuka T, Adachi H, Nakashima I.
Long-term effectiveness and safety of satralizumab for neuromyelitis optica spectrum disorder in a real-world clinical setting in Japan: A 2.5-year final analysis of a multicenter medical chart review
(The SAkuraBeyond Study).
Mult Scler, 2026 NEW Jan, in press
Usuki N, Ueda T, Takeuchi M, Morimoto M, Tsuboi Y, Yamamoto R, Takaishi S, Tatsuno K, Ito H, Shimizu T, Yamano Y, on behalf of the K-NET Registry Investigators.
Recent Outcomes of Intravenous tissue Plasminogen Activator (t-PA) Alone in the Era of Mechanical Thrombectomy: A Sub-analysis of the Kanagawa Intravenous and Endovascular Treatment (K-NET) Registry.
Clin Neurol Neurosurg, 2026 NEW Jan, in press
Kimura A, Takekoshi A, Maekawa Y, Tanaka K, Yamano Y, Saito K, Takemura M, Shimohata T.
Investigation of Prognostic Factors in Patients with Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy.
Eur J Neurol. 2026 NEW Jan;33(1):e70489. doi: 10.1111/ene.70489.